Patent Issued for Inhibitors of Bruton's tyrosine kinase and method of their use (USPTO 12065446).

A patent has been issued for inhibitors of Bruton's tyrosine kinase (BTK) and their use in treating cancer. The patent, assigned to Janssen Pharmaceutica NV, describes compounds that can be administered to patients with mantle cell lymphoma, chronic lymphocytic leukemia, macroglobulinemia, or multiple myeloma. BTK is a protein that plays a role in the growth and differentiation of blood and endothelial cells. The compounds described in the patent have the potential to modulate biology associated with B cells, macrophages, mast cells, osteoclasts, and platelet microparticles. [Extracted from the article]